Evaluation of species distribution and antifungal susceptibility profiles of Candida isolates from hospitalized patients;Yatan hasta örneklerinden izole edilen Candida izolatlarinin tür dağilimlarinin ve antifungal duyarlilik profillerinin değerlendirilmesi

Turk Hijyen ve Deneysel Biyoloji Dergisi

Volumn 72, Issue 1, 2015, Pages 17-26

  Hazirolan, Gülşen ^a   Yildiran, Dilara ^a   Baran, Irmak ^a   Mumcuoğlu, Ipek ^a   Aksu, Neriman ^a  

^a Ankara Numune Egitim ve Arastirma Hastanesi   (Turkey)

Author keywords

Antifungal susceptibility profiles; Candida; Species distribution

Indexed keywords

EID: 84928406377     PISSN: 03779777     EISSN: None     Source Type: Journal    
DOI: 10.5505/TurkHijyen.2015.75010     Document Type: Article

References (32)

1. Cornely OA. Aspergillus to zygomycetes: causes, risk faktors, prevention, and treatment of invasive fungal infections. Infection, 2008; 36 (4): 296-313.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent problem. Clin Microbiol Rev, 2007; 20 (1): 133-63.
3. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am, 2006; 20 (3): 485-506.
4. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis, 2012; 73 (1): 45-8.
5. Lewis RE. Overview of the changing epidemiology of candidemia. Curr Med Res Opin, 2009; 25 (7): 1732-40.
6. Hazen KC, Howell SA. Candida, Cryptococcus ve Tibbi Önemi Olan Diger Mayalar, 9ncu baski, Ankara: Atlas Kitapçilik, 2009.
7. Dignani MC, Solomkin JS, Anaissie EJ. Clinical Mycology. 2nd, Churchill Livingstone: Elsevier Inc, 2009.
8. Anonymous. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. CLSI Document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, 2008.
9. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al.. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev, 2001; 14 (4): 643-58.
10. Anonymous. Method for antifungal disk diffusion susceptibility testing of yeasts; Approved Guideline 2nd, CLSI document M44-A2. Clinical and Laboratory Standards Institute, Wayne, Pa, 2009.
11. Anonymous. Refererence method for broth dilution antifungal susceptibility testing of yeast; approved Standard, 3rd ed. CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, Pa. 2008.
12. Cuenca-Estrella M, Gomez-Lopez A, Alastruey- Izquierdo A, Bernal-Martinez L, Cuesta I, Maria J, et al.. Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference methods and with the sensititre yeast one and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. Clin Microbiol, 2010; 48 (5): 1782-6.
13. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol, 2011; 49 (1): 396-9.
14. Yapar N, Pullukcu H, Avkan-Oguz V, Sayin-Kutlu S, Ertugrul B, Sacar S. Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. Med Mycol, 2011; 49 (1): 26-31.
15. Çalişkan E, Dede A, Biten G. Kan Kültürlerinde saptanan Candida türlerinin dağilimi ve antifungal duyarliliklari. ANKEM, 2013; 27 (1): 25-30.
16. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis, 1998; 27 (4): 781-8.
17. Acar A, Öncül O, Küçükardali Y, Özyurt M, Haznedaroğlu T, Çavuşlu S. Yoğun bakim ünitelerinde saptanan Candida enfeksiyonlarinin epidemiyolojik özellikleri ve mortaliteye etki eden risk faktörleri. Mikrobiyol Bul, 2008; 42(3): 451-61.
18. Çekin Y, Pekintürk N, Cekin AH. Evaluation of species distribution and antifungal resistance of Candida isolates from hospitalized patients. J Clin Anal Med, 2015; 6(1): 8-11.
19. Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, et al.. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol, 2012; 50 (12): 3952-9.
20. Azevedo AC, Bizerra FC, da Matta DA, de Almeida LP, Rosas R, Colombo AL. In vitro susceptibility of a large collection of Candida strains against fluconazole and voriconazole by using the CLSI disk diffusion assay. Mycopathologia, 2011; 171 (6): 411-6.
21. Odds FC, Hanson MF, Davidson D, Jacobsen MD, Wright P, Whyte JA, et al.. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol, 2007; 56 (8): 1066-75.
22. Messer SA, Jones RN, Moet GJ, Kirby JT, Castanheira M. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp. results from the global SENTRY Antimicrobial Surveillance Program (2008) J Clin Microbiol, 2010; 48 (8): 2984-7.
23. Sook-In J, Jong HS, Hyun-Jung C, Min-Young JMS, Soo-Hyun K, Wee Gyo L, et al.. Korean Study Group for Candidemia. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea. Ann Lab Med, 2012; 32(6): 426-8.
24. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis, 2009; 48 (5): 503-35.
25. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev, 2007; 20 (1): 133-63.
26. Doğruman AL, Aktaş AE, Tuncel E, Ayyildiz A, Yiğit N. Yenidoğan kan kültürlerinden izole edilen Candida kökenlerinin standart makrodilüsyon ve E test yöntemleriyle antifungal duyarliliklarinin saptanmasi. XXIX. Türk Mikrobiyoloji Kongresi. 8-13 Ekim, Antalya-Türkiye. 2000.
27. Findik D, Tuncer I, Arslan U. Candida albicans türü maya mantarlarinda antifungal ilaç direnci. XXIX. Türk Mikrobiyoloji Kongresi. Ekim 8-13, Antalya- Türkiye. 2000.
28. Zer Y, Balci I. Yoğun Bakim ünitesindeki hastalardan izole edilen Candida suşlarinin identifikasyonu ve antifungal duyarliliklari. Türk Mikrobiyol Cem Derg, 2002; 32(3): 230-4.
29. Cheng MF1, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis, 2004; 48 (1): 33-7.
30. Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents, 2010; 35 (3): 211-8.
31. Spiliopoulou A, Vamvakopoulou S, Bartzavali C, Dimitracopoulos G, Anastassiou ED, Christofidou M. Eleven- year retrospective survey of candidemia in a University Hospital in Southwestern Greece. Clin Microbiol Infect, 2010; 16 (9): 1378-81.
32. Saracli MA, Gumral R, Gul HC, Gonlum A, Yildiran ST. Species distribution and in vitro susceptibility of Candida bloodstream isolates to six new and current antifungal agents in a Turkish tertiary care military hospital, recovered through 2001 and 2006. Mil Med, 2009; 174 (8): 860-5.